...
首页> 外文期刊>Pharmacological reports: PR >Synthesis and pharmacological properties of new, GABA uptake inhibitors
【24h】

Synthesis and pharmacological properties of new, GABA uptake inhibitors

机译:新型GABA吸收抑制剂的合成和药理特性

获取原文
获取原文并翻译 | 示例

摘要

Background: γ-Aminobutanoic acid (GABA) is the principal inhibitory neurotransmitter in the mammalian central nervous system. The identification and subsequent development of the GABAtransport inhibitors which enhance the GABA-ergic transmission has shown the important role that GABA transporters play in the control of numerous functions of the nervous system. Compounds which inhibit GABAuptake are used as antiepileptic drugs (tiagabine - a selective GAT1 inhibitor), they are also being investigated for other indications, including treatment of psychosis, general anxiety, sleep disorders, drug addiction or acute and chronic pain. Methods: In this paper, the synthesis of 2-substituted-4-(1,3-dioxoisoindolin-2-ylo)-butanamides and 2-substituted-4- aminobutanoic acids derivatives is described. These compounds were tested in vitro for their ability to inhibit GABA uptake. The inhibitory potency towards murine plasma membrane GABA transporters (mGAT1-4) was performed as [3H]GABA uptake assay based on stably transfected HEK cells. Compound 18, which demonstrated the highest affinity for mGAT1-4 (pIC50 ranged from 4.42 for mGAT1 to 5.07 for mGAT3), was additionally investigated in several behavioral tests in mice. Results: Compound 18 increased the locomotor activity (14-38%) and had anxiolytic-like properties in the four-plate test (ED50 = 9.3 mg/kg). It did not show analgesic activity in acute pain model, namely the hot plate test, however, it was antinociceptive in the acetic acid-induced writhing test (ED50 = 15.3 mg/kg) and in the formalin model of tonic pain. In the latter assay, it diminished nocifensive behavior in both phases and in the first (neurogenic) phase of this test the obtained ED50 value (5.3 mg/kg) was similar to morphine (3.0 mg/kg). Conclusion: Compound 18 exhibited significant anxiolytic-like properties and was antinociceptive in some models of pain in mice. Moreover, it did not impair animals' motor coordination in the chimney test. Some of the described pharmacological activities of compound 18 can be partly explained based on its affinity for plasma membrane GABA transporters.
机译:背景:γ-氨基丁酸(GABA)是哺乳动物中枢神经系统中的主要抑制性神经递质。增强GABA能传递的GABA运输抑制剂的鉴定和后续开发表明,GABA转运蛋白在控制神经系统的许多功能中起着重要作用。抑制GABA摄取的化合物用作抗癫痫药(替加滨-选择性GAT1抑制剂),也正在研究它们的其他适应症,包括治疗精神病,一般性焦虑,睡眠障碍,药物成瘾或急性和慢性疼痛。方法:在本文中,描述了2-取代的4-(1,3-二氧代异吲哚啉-2-基)-丁酰胺和2-取代的-4-氨基丁酸衍生物的合成。在体外测试了这些化合物抑制GABA摄取的能力。对鼠质膜GABA转运蛋白(mGAT1-4)的抑制效能是根据稳定转染的HEK细胞进行的[3H] GABA吸收测定。化合物18对mGAT1-4具有最高的亲和力(pIC50范围从mGAT1的4.42到mGAT3的5.07),另外在小鼠的一些行为测试中进行了研究。结果:在四板试验中,化合物18增加了运动活性(14-38%),并具有类似抗焦虑的特性(ED50 = 9.3 mg / kg)。在急性疼痛模型(即热板试验)中未显示镇痛作用,但是在乙酸诱导的扭体试验(ED50 = 15.3 mg / kg)和福尔马林补品疼痛模型中,它没有镇痛作用。在后一种测定中,它减弱了这两个阶段的伤害行为,并且在该测试的第一(神经源性)阶段,获得的ED50值(5.3 mg / kg)与吗啡(3.0 mg / kg)相似。结论:化合物18在小鼠的某些疼痛模型中表现出显着的抗焦虑性质,并且具有镇痛作用。而且,它在烟囱测试中没有损害动物的运动协调能力。所述化合物18的某些药理活性可以部分基于其对质膜GABA转运蛋白的亲和力来解释。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号